Previous 10 | Next 10 |
Significant Progress Achieved Against Strategic Priorities for ATA188, Tab-cel ® and CAR T Programs in 2021 ATA188 Granted FDA Fast Track Designation for Both Non-Active PPMS and Non-Active SPMS in Recognition of Potential to Address Significant Unmet Medical Need ...
Relationship Will Leverage Be The Match BioTherapies’ Expertise and Expansive Donor Registry to Provide Healthy Donor Cells in Support of Atara’s Allogeneic T-cell Platform Be The Match BioTherapies and Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announce...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President...
Galera Therapeutics (NASDAQ:GRTX) +138% announces primary endpoint met statistical significance in corrected topline efficacy data of phase 3 ROMAN trial of avasopasem. Nuverra Environmental Solutions (NYSE:NES) +33%. Terminix Global Holdings (NYSE:TMX) +25%. MIND Technology (NASDAQ:MIND...
Phase 3 ALLELE Study in EBV+ PTLD Demonstrates 50% Objective Response Rate, Consistent with Previous Results At Least 11 of 19 Responders had a Duration of Response (DOR) Lasting More Than Six Months with Median Time to Response in All Patients of Just 1.1 Months One-y...
Atara has been stagnant because of more than a year's worth of delay caused by the CMC review division at the FDA. I see no immediate end to the process; however, this has nearly nothing to do with the asset's viability as a treatment option for EBV-PTLD. I am hoping for the best ...
Atara Biotherapeutics (NASDAQ:ATRA) has disclosed new preclinical and preliminary clinical results for ATA2271, an autologous chimeric antigen receptor (CAR) T-cell therapy candidate targeted at mesothelin (MSLN). The early data for ATA2271 were included in a presentation conducted at 2021 Eu...
ATA2271 targets difficult-to-treat solid tumors using proprietary 1XX CAR signaling and intrinsic PD-1 checkpoint inhibition technology Ongoing Phase 1 dose-escalation trial in advanced mesothelioma shows promising early safety and persistence of armored CAR T cells in patient...
Atara Biotherapeutics (NASDAQ:ATRA) granted 21,438 restricted stock units of Atara's common stock to seven newly hired employees and stock options to purchase 24,017 shares to four such newly hired employees. The restricted stock units vest over four years, with 25% vesting on ...
First-Ever Off-The-Shelf Allogeneic T-Cell Therapy to be Reviewed by any Regulatory Agency in the World EMA Priority Medicines (PRIME) and Orphan Designated Tabelecleucel One Step Closer for Patients with High Unmet Need EU Approval Decision Anticipated for Second Half...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...